Also known as: Amyotrophic Lateral Sclerosis (ALS)
ALS is a progressive neurodegenerative disease that affects motor neurons in the brain and spinal cord, leading to loss of muscle control. It gradually impairs the ability to move, speak, eat, and eventually breathe.
ALS affects approximately 2 per 100,000 people annually worldwide. It is characterised by progressive degeneration of both upper and lower motor neurons, leading to muscle weakness, atrophy, and eventually paralysis.
About 90–95% of cases are sporadic (no clear cause), while 5–10% are familial (genetic). The disease typically begins with focal weakness — either limb onset (most common) or bulbar onset (affecting speech and swallowing first).
Average survival from symptom onset is 2–5 years, though about 10% of patients survive more than 10 years. Research into disease mechanisms and treatments is accelerating, with several new therapies in clinical trials.
People with ALS (Lou Gehrig's Disease) often experience the following symptoms.
Typically begins in one limb — difficulty gripping, tripping, or foot drop. Weakness gradually spreads to other body regions over months.
Slurred speech (dysarthria), difficulty swallowing (dysphagia), and excessive saliva or drooling indicate involvement of the muscles controlling speech and swallowing.
Visible muscle twitching or rippling under the skin, caused by spontaneous firing of dying motor neurons.
Weakness of the diaphragm and breathing muscles leads to shortness of breath, particularly when lying down, and eventually respiratory failure.
Certain factors may increase your likelihood of developing ALS (Lou Gehrig's Disease).
Common approaches to managing als (lou gehrig's disease). Always consult a healthcare provider for personalized treatment.
The first FDA-approved ALS medication, riluzole modestly slows disease progression by reducing glutamate toxicity, extending survival by a few months.
An antioxidant that may slow functional decline in some ALS patients, administered intravenously or orally.
Coordinated care from neurologists, respiratory therapists, speech therapists, physiotherapists, and nutritionists significantly improves quality of life.
Non-invasive ventilation (BiPAP) improves quality of life and extends survival when breathing muscles weaken.
Diagnosis is primarily clinical, based on progressive upper and lower motor neuron signs in multiple body regions. EMG and nerve conduction studies confirm motor neuron involvement. MRI and blood tests rule out mimicking conditions. The revised El Escorial criteria guide diagnosis.
See a neurologist if you experience progressive weakness, muscle wasting, persistent twitching, or difficulty with speech and swallowing that is not explained by other conditions.
Steps that may help reduce the risk of developing or worsening als (lou gehrig's disease).
No proven prevention exists
Genetic counselling for families with hereditary ALS
Research into environmental risk factors is ongoing
Clinical trial participation supports future treatments
If left untreated or poorly managed, als (lou gehrig's disease) may lead to:
ALS primarily affects motor function. However, about 10–15% of patients develop frontotemporal dementia, and up to 50% may have subtle cognitive or behavioural changes.
About 5–10% of cases are familial. Known genetic mutations include SOD1, C9orf72, and others. Genetic testing and counselling are available for affected families.
Average survival from symptom onset is 2–5 years. However, there is significant variability — about 10% of patients live more than 10 years. Stephen Hawking famously lived over 50 years with the disease.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.